Tarlatamab

• CAT Number: I042116
• CAS Number: 2307488-83-9
• Purity: ≥95%

Tarlatamab (Cat No.: I042116) is a bispecific T-cell engager (BiTE) antibody that targets delta-like ligand 3 (DLL3), a protein overexpressed in small cell lung cancer (SCLC), and CD3 on T cells. By bridging T cells to DLL3-positive tumor cells, Tarlatamab promotes targeted cytotoxicity and tumor cell lysis. It is designed to harness the body’s immune response against difficult-to-treat cancers. Tarlatamab is currently under clinical investigation for its potential to treat relapsed or refractory SCLC and other DLL3-expressing neuroendocrine tumors.

Reference

[1]. Michael J Giffin, et al. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer. Clin Cancer Res. 2021 Mar 1;27(5):1526-1537.
[Content Brief]